While the term is nothing new, the focus on the topic of real-world evidence is suddenly reaching a fever pitch, and that’s understandable. Demands from payers, patients, prescribers, and regulators for definitive data have never been greater.
real world evidence
Manufacturers of biopharmaceutical products and medical devices understand that the regulatory approval of their product will bring postmarketing challenges, requiring strategic and innovative solutions for continued surveillance of product safety and for demonstrating value and effectiveness based on real world evidence.
Last week, medical affairs leaders gathered in London for NextLevel’s Medical Affairs Forum. At the congress, I was honored to chair the Best Practices in Late Phase Research track and meet with many industry leaders. Presenters shared their innovative views on integrating real-world evidence within product lifecycle strategies along with perspectives on study design and implementation challenges and opportunities.